By Mass General Brigham –
A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson’s disease in which a patient’s stem cells are reprogrammed to replace dopamine cells in the brain damaged by the disease. The first-of-its-kind trial of an autologous stem cell transplant, based on research and technologies invented and validated preclinically at McLean Hospital’s Neuroregeneration Research Institute (NRI), has enrolled and treated three patients at Brigham and Women’s Hospital.
- Phase 1 trial reprograms patient’s own stem cells to replace dopamine neurons in the brain
- Work is born out of three decades of preclinical research led by McLean Hospital and Ole Isacson
- First-of-its-kind trial has treated three-of-six participants who will be tracked for more than a year
